Patent EP0459318A2 successfully refreshed from Google Patents.
EP0459318A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method for preventing onset of restenosis after angioplasty employing an ACE inhibitor
Assignee: ER Squibb and Sons LLC
•
Filing: 1991-05-24
•
Granted: —
•
Expires: 2011-05-24
Abstract
Abstract A method is provided for preventing or reducing the risk of restenosis following angioplasty by administering an ACE inhibitor such as fosinopril or ceranapril, prior to, during and/or after angioplasty.
Inventors
- 👤 Miguel A. Ondetti
- 👤 Gunnar A.K. Aberg
- 👤 Patricia Ferrer
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-29 23:38
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66; A61K31/675; A61K31/33; A61K31/395; A61K31/40; A61K38/00; A61K38/16; A61K38/55; A61K38/556; A61P; A61P43/00; A61P7/00; A61P7/02; A61P9/00; A61P9/08; A61P9/10
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
30 words
Use of an angiotensin converting enzyme inhibitor for manufacturing a medicament for preventing or reducing the risk of restenosis following angioplasty in a mammalian specie in need of such treatment.
Claim 2
Dependent Claim
15 words
The use of claim 1 wherein said angiotensin converting enzyme inhibitor is a phosphorus-containing compound.
Claim 3
Dependent Claim
25 words
The use of claim 2 wherein said phosphorus-containing compound is selected from phosphonate substituted amino or imino acids, Phosphinylalkanoyl prolines, phosphinylalkanoyl substituted prolines or phosphonamidates.
Claim 4
Dependent Claim
15 words
The use of claim 2 wherein said phosphorus-containing compound is selected from fosinopril and ceranapril.
Claim 5
Dependent Claim
16 words
The use as defined in claim 1 wherein the medicament is for administration prior to angioplasty.
Claim 6
Dependent Claim
15 words
The use as defined in claim 1 wherein the medicament is for administration during angioplasty.
Claim 7
Dependent Claim
15 words
The use as defined in claim 1 wherein the medicament is for administration after angioplasty.
Claim 8
Dependent Claim
34 words
The use as defined in claim 1 wherein said medicament is manufactured in dosage forms containing 0.1 to 500 mg angiotensin converting enzyme for administration in single or divided doses/one to four times daily.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.